Everybody has a Superhero
News,
Craig Stankiewicz is a husband, father and business professional from Chicago, Illinois. In August 2021, Craig was diagnosed with glioblastoma (GBM) and almost five years on he continues to face…
Read moreNews & Views
Telix at ASCO 2026
News,
Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago. ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of…
Read more
Telix at SNMMI 2026
News,
Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting. This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel…
Read more
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
News,
Telix advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies…
Read more
Fighting for Every Day
News,
Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother,…
Read more
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
News,
Telix today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including…
Read more
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
News,
Telix today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A.(NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading…
Read more
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
News,
Telix today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology, demonstrating that TLX250‑Px (Zircaix®, 89Zr-girentuximab) PET/CT imaging may be highly predictive…
Read more
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate, has been validated and accepted for…
Read more
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
News,
Telix today announces dosimetry results from the randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in metastatic castration-resistant prostate cancer (mCRPC), presented at the 2026 International Prostate Cancer Symposium (IPCS 2026)…
Read more